Arcutis Submits Supplemental NDA For ZORYVE Foam To The FDA For The Treatment Of Scalp And Body Psoriasis In Adults And Adolescents Ages 12 And Over
$ARQT
Biotechnology: Pharmaceutical Preparations
Health Care
- Approximately 40% of the 9 million individuals in the United States with plaque psoriasis experience involvement of the scalp
- Once-daily ZORYVE foam significantly improved both scalp and body psoriasis in a Phase 2b and a pivotal Phase 3 trial
- Data also show rapid reduction in scalp itch as soon as 24 hours after first application
- ZORYVE foam demonstrated a favorable safety and tolerability profile
WESTLAKE VILLAGE, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the submission of a supplemental New Drug Application (sNDA) for ZORYVE (roflumilast) foam 0.3%, a once-daily, next generation phosphodiesterase-4 (PDE4) inhibitor, for the treatment of adults and adolescents ages 12 and over with scalp and body psoriasis.